Key result
Evolut PRO TAVR demonstrates sustained hemodynamic performance and improved paravalvular regurgitation over 5 years.
Why the study?
The long-term performance and durability of the Evolut PRO transcatheter heart valve in elderly patients with severe aortic stenosis and elevated operative risk were not fully established.
Does TAVR with the Evolut PRO valve provide durable hemodynamic performance and clinical outcomes over 5 years in elderly patients with severe aortic stenosis and elevated operative risk?
Observational
Yes
Does TAVR with the Evolut PRO valve provide durable hemodynamic performance and clinical outcomes over 5 years in elderly patients with severe aortic stenosis and elevated operative risk?
TAVR with the Evolut PRO valve shows durable hemodynamic performance and favorable clinical outcomes at 5 years in high-risk elderly patients with severe aortic stenosis.
May inform Evolut PRO selection in high-risk elderly patients; extends Level 5 evidence for sustained hemodynamics and improving regurgitation to 5 years.
•TAVR with the Evolut PRO valve in elderly patients with severe aortic stenosis and an elevated operative risk is associated with favorable clinical outcomes.•TAVR with Evolut PRO has favorable hemodynamic valve performance that persisted for up to 5 years in patients with available echocardiographic follow-up.•Paravalvular regurgitation improves over time in most patients with paravalvular regurgitation after TAVR with the EVOLUT PRO valve.
No takes yet. Share an insight, caveat, or question.
Windecker et al. (2026) conducted an observational in Severe aortic stenosis. TAVR with the Evolut PRO valve was evaluated. TAVR with the Evolut PRO valve in elderly patients with severe aortic stenosis demonstrated favorable clinical outcomes, sustained hemodynamic performance, and improved paravalvular regurgitation over 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: